Neurocrine Biosciences (NBIX) Change in Cash (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Change in Cash of $64.4 million for Q2 2026, down 7.87% year-over-year from $69.9 million in Q2 2025, and up 114.42% on a QoQ basis from -$446.5 million in Q1 2026.
Neurocrine Biosciences (NBIX) Change in Cash (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Change in Cash for 17 years, with the latest figure at $64.4 million in Q2 2026.
- Change in Cash for Q2 2026 came in at $64.4 million, down 7.87% year-over-year; the trailing twelve-month figure through Jun 2026 was $66.9 million (down 46.18% YoY), and the FY2025 annual result was $480.0 million, up 2751.93% from the prior year.
- Change in Cash grew to $64.4 million in Q2 2026, from -$446.5 million in the prior quarter.
- Over five years, Change in Cash peaked at $372.8 million in Q4 2025 and troughed at -$446.5 million in Q1 2026.
- A 5-year average of -$283333.3 and a median of $49.8 million in 2022 frame the typical range for Change in Cash.
- The widest annual swing landed in 2025, when Change in Cash jumped 421.1%; it then tumbled 1047.81% in 2026.
- A 5-year view of Change in Cash shows it stood at $50.7 million in 2022, then tumbled by 184.02% to -$42.6 million in 2023, then plunged by 172.54% to -$116.1 million in 2024, then jumped by 421.1% to $372.8 million in 2025, then sank by 82.73% to $64.4 million in 2026.
- Per Business Quant data, the three most recent Change in Cash figures were $64.4 million in Q2 2026, -$446.5 million in Q1 2026, and $372.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -86.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -465.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -915.70 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 102.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.07 Bn | 7.41 Bn | 397.90 Mn | 159.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64.40 Mn |
| Mar 31, 2026 | -446.50 Mn |
| Dec 31, 2025 | 372.80 Mn |
| Sep 30, 2025 | 76.20 Mn |
| Jun 30, 2025 | 69.90 Mn |
| Mar 31, 2025 | -38.90 Mn |
| Dec 31, 2024 | -116.10 Mn |
| Sep 30, 2024 | 209.40 Mn |
| Jun 30, 2024 | -256.60 Mn |
| Mar 31, 2024 | 145.20 Mn |
| Dec 31, 2023 | -42.60 Mn |
| Sep 30, 2023 | 133.50 Mn |
| Jun 30, 2023 | 56.60 Mn |
| Mar 31, 2023 | -159.10 Mn |
| Dec 31, 2022 | 50.70 Mn |
| Sep 30, 2022 | 48.90 Mn |
| Jun 30, 2022 | -106.90 Mn |
| Mar 31, 2022 | -66.00 Mn |
| Dec 31, 2021 | 29.70 Mn |
| Sep 30, 2021 | -56.90 Mn |